低剂量甲氨蝶呤治疗中代谢功能障碍相关脂肪性肝病风险患者Fibrosis-4的纵向随访
该文关注接受低剂量甲氨蝶呤治疗、存在代谢功能障碍相关脂肪性肝病(MASLD)风险的患者,纵向随访其Fibrosis-4(FIB-4)评分。文中指出FIB-4最初用于评估人类免疫缺陷病毒与丙型肝炎病毒共感染者的肝纤维化,现广泛用于监测非酒精性脂肪性肝病(现称MASLD)患者的肝纤维化严重程度。
要点
- FIB-4最初用于评估人类免疫缺陷病毒与丙型肝炎病毒共感染者的肝纤维化。
- FIB-4已广泛用于监测非酒精性脂肪性肝病(现称MASLD)患者的肝纤维化严重程度。
- 多种非侵入性肝纤维化检测已开发,可能替代侵入性肝活检作为监测工具。
核心结论
- 多种非侵入性肝纤维化检测已开发,可能预测纤维化严重程度,并可能替代侵入性肝活检作为监测工具。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Several noninvasive liver fibrosis tests have been developed and appear to predict the severity of fibrosis, possibly replacing invasive liver biopsy as a monitoring tool.1 The fibrosis-4 (FIB-4) score originally was proposed to help assess liver fibrosis in patients with human immunodeficiency virus and hepatitis C virus co-infection.1 FIB-4 has been used widely to monitor the severity of liver fibrosis, especially in patients with nonalcoholic fatty liver disease,2 now termed metabolic dysfunction-associated steatotic liver disease (MASLD).3.
引用
- Cui J, Di Martino V, Solomon DH, et al. Longitudinal Follow-Up of Fibrosis-4 in Patients at Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease Receiving Low-Dose Methotrexate Treatment. Clin Gastroenterol Hepatol. 2024. PMID: 38663834. doi:10.1016/j.cgh.2024.03.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。